Keywords: ucb, drugs, miss, ph, iia, endpoints, future
Two UCB drugs miss Ph IIa endpoints; future in doubt
Article | 02 March 2009
UCB says that both lacosamide in migraine prophylaxis and rotigotine in fibromyalgia syndrome failed to achieve statistical significance for their ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
